StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Morgan Stanley Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 7, 2016 6:32 AM
Morgan Stanley downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Downgrades
Next Articles
Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
October 5, 2016 4:31 PM
Alnylam Pharmaceuticals Discontinues Revusiran Development
October 5, 2016 4:30 PM
